SparingVision
Paris
About SparingVision
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $127.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2022)
- Website: sparingvision.com
- Phone: +33(0)1 43 46 20 60
Industries & Categories
Biotechnology, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/sparingvision-83403 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.